Cyclacel Pharmaceuticals

About:

Cyclacel Pharmaceuticals develops oral therapies to treat cancers and other critical diseases.

Website: http://cyclacel.com

Top Investors: Temasek Holdings, UOB Venture, DC Thomson, Scottish Equity Partners, HBM Partners

Description:

Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Professor Sir David Lane, a recognized leader in the field of tumor suppressor biology, who discovered the p53 protein, founded the Company in 1996. In 1999, Cyclacel Pharmaceuticals was joined by Professor David Glover, a recognized leader in the mechanism of mitosis or cell division, who discovered, among other cell cycle targets, the mitotic kinases, Polo and Aurora, enzymes that act in the mitosis phase of the cell cycle.